Overcoming presynaptic effects of VAMP2 mutations with 4‐aminopyridine treatment
Open Access
- 9 September 2020
- journal article
- research article
- Published by Wiley in Human Mutation
- Vol. 41 (11) , 1999-2011
Abstract
Clinical and genetic features of five unrelated patients with de novo pathogenic variants in the synaptic vesicle‐associated membrane protein 2 (VAMP2) reveal common features of global developmental delay, autistic tendencies, behavioral disturbances, and a higher propensity to develop epilepsy. For one patient, a cognitively impaired adolescent with a de novo stop‐gain VAMP2 mutation, we tested a potential treatment strategy, enhancing neurotransmission by prolonging action potentials with the aminopyridine family of potassium channel blockers, 4‐aminopyridine and 3,4‐diaminopyridine, in vitro and in vivo. Synaptic vesicle recycling and neurotransmission were assayed in neurons expressing three VAMP2 variants by live‐cell imaging and electrophysiology. In cellular models, two variants decrease both the rate of exocytosis and the number of synaptic vesicles released from the recycling pool, compared with wild‐type. Aminopyridine treatment increases the rate and extent of exocytosis and total synaptic charge transfer and desynchronizes GABA release. The clinical response of the patient to 2 years of off‐label aminopyridine treatment includes improved emotional and behavioral regulation by parental report, and objective improvement in standardized cognitive measures. Aminopyridine treatment may extend to patients with pathogenic variants in VAMP2 and other genes influencing presynaptic function or GABAergic tone, and tested in vitro before treatment.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (NS058721)
- National Institute of Mental Health (MH066198, MH083691)
This publication has 29 references indexed in Scilit:
- SNARE motif-mediated sorting of synaptobrevin by the endocytic adaptors clathrin assembly lymphoid myeloid leukemia (CALM) and AP180 at synapsesProceedings of the National Academy of Sciences, 2011
- A small recurrent deletion within 15q13.3 is associated with a range of neurodevelopmental phenotypesNature Genetics, 2009
- Improving the photostability of bright monomeric orange and red fluorescent proteinsNature Methods, 2008
- Synaptotagmin-12, a synaptic vesicle phosphoprotein that modulates spontaneous neurotransmitter releaseJournal of Cell Biology, 2006
- Molecular Anatomy of a Trafficking OrganelleCell, 2006
- SNAREs — engines for membrane fusionNature Reviews Molecular Cell Biology, 2006
- Synaptobrevin is essential for fast synaptic-vesicle endocytosisNature Cell Biology, 2004
- Identification of a Minimal Core of the Synaptic SNARE Complex Sufficient for Reversible Assembly and DisassemblyBiochemistry, 1998
- Endocytosis of VAMP is facilitated by a synaptic vesicle targeting signal.Journal of Cell Biology, 1996
- 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia.Journal of Neurology, Neurosurgery & Psychiatry, 1991